Hypoglycaemia is an important concern in diabetic patients. A new insulin glargine injection (300 units/mL) or Gla-300, launched in South Africa on 21 April, has been shown to reduce the risk of nocturnal hypoglycaemia in patients by up to 31% in real world settings. Anytime hypoglycaemia was reduced by 14%.

The new Gla-300 insulin launched by Sanofi reduces hypoglycaemia.

Please sign in to read more